✦ LIBER ✦

Initial experience with the intravascular contrast agent NC100150-injection (Clariscan®) for breath-hold and navigator-gated magnetic resonance coronary artery imaging

✍ Scribed by Nicholas H. Bunce; Jennifer Keegan; Peter D. Gatehouse; James C.C. Moon; David N. Firmin; Volker Hoffmann; Dudley J. Pennell

Publisher: John Wiley and Sons
Year: 2002
Tongue: English
Weight: 803 KB
Volume: 16
Category: Article
ISSN: 1053-1807
DOI: 10.1002/jmri.10151

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Purpose

To examine magnetic resonance coronary artery imaging after NC100150‐Injection.

Materials and Methods

Breath‐hold and navigator‐gated images were acquired in five patients.

Results

Breath‐hold image quality, coronary artery‐fat SDNR, and coronary artery SNR improved. Respiratory artifacts due to reduced liver signal intensity degraded navigator‐gated image quality.

Conclusion

NC100150‐Injection improves breath‐hold coronary artery imaging. Navigator‐gated acquisitions should use techniques that are insensitive to T2* effects. J. Magn. Reson. Imaging 2002;16:217–223. © 2002 Wiley‐Liss, Inc.

📜 SIMILAR VOLUMES

Improvement of image quality of non-inva

Improvement of image quality of non-invasive coronary artery imaging with magnetic resonance by the use of the intravascular contrast agent Clariscan™ (NC100150 injection) in patients with coronary artery disease

✍ Christoph Klein; Simon Schalla; Bernhard Schnackenburg; Axel Bornstedt; Volker H 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 803 KB

## Abstract ## Purpose To assess the feasibility of Clariscan™, an intravascular contrast agent, for free breathing, navigator assisted, high resolution, three‐dimensional‐magnetic resonance coronary angiography (MRCA) in patients, as extracellular contrast agents are unfavorable for the improveme